{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161v1.1","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10021","date":"2021-03-04T21:35:28.386Z","role":"Publisher"},{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10021","date":"2018-07-24T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:523d9870-c249-4562-89c0-33e5f9e7b1f6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cf8bd4de-f6ff-4ae9-bb70-efc7270c5e9b","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Established gene in RAS pathway which is established in RASopathies","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23875798","type":"dc:BibliographicResource","dc:abstract":"The RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. These disorders include neurofibromatosis type 1, Noonan syndrome, Noonan syndrome with multiple lentigines, capillary malformation-arteriovenous malformation syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, and Legius syndrome. Because of the common underlying Ras/MAPK pathway dysregulation, the RASopathies exhibit numerous overlapping phenotypic features. The Ras/MAPK pathway plays an essential role in regulating the cell cycle and cellular growth, differentiation, and senescence, all of which are critical to normal development. Therefore, it is not surprising that Ras/MAPK pathway dysregulation has profound deleterious effects on both embryonic and later stages of development. The Ras/MAPK pathway has been well studied in cancer and is an attractive target for small-molecule inhibition to treat various malignancies. The use of these molecules to ameliorate developmental defects in the RASopathies is under consideration. ","dc:creator":"Rauen KA","dc:date":"2013","dc:title":"The RASopathies."},"rdfs:label":"BRAF is in RAS pathway"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5,"dc:description":"Awarded functional evidence for gene being in RAS pathway"}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:ea908245-5c41-4df8-a7d8-70996e798400","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cd02c39f-ebc5-45a9-a828-dcbaeb8f0875","type":"FunctionalAlteration","dc:description":"Both variants led to a slight increase in the phosphorylation levels of MEK and ERK. See Fig 3B.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19206169","type":"dc:BibliographicResource","dc:abstract":"Noonan, LEOPARD, and cardiofaciocutaneous syndromes (NS, LS, and CFCS) are developmental disorders with overlapping features including distinctive facial dysmorphia, reduced growth, cardiac defects, skeletal and ectodermal anomalies, and variable cognitive deficits. Dysregulated RAS-mitogen-activated protein kinase (MAPK) signal traffic has been established to represent the molecular pathogenic cause underlying these conditions. To investigate the phenotypic spectrum and molecular diversity of germline mutations affecting BRAF, which encodes a serine/threonine kinase functioning as a RAS effector frequently mutated in CFCS, subjects with a diagnosis of NS (N=270), LS (N=6), and CFCS (N=33), and no mutation in PTPN11, SOS1, KRAS, RAF1, MEK1, or MEK2, were screened for the entire coding sequence of the gene. Besides the expected high prevalence of mutations observed among CFCS patients (52%), a de novo heterozygous missense change was identified in one subject with LS (17%) and five individuals with NS (1.9%). Mutations mapped to multiple protein domains and largely did not overlap with cancer-associated defects. NS-causing mutations had not been documented in CFCS, suggesting that the phenotypes arising from germline BRAF defects might be allele specific. Selected mutant BRAF proteins promoted variable gain of function of the kinase, but appeared less activating compared to the recurrent cancer-associated p.Val600Glu mutant. Our findings provide evidence for a wide phenotypic diversity associated with mutations affecting BRAF, and occurrence of a clinical continuum associated with these molecular lesions.","dc:creator":"Sarkozy A","dc:date":"2009","dc:title":"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum."},"rdfs:label":"Functional alteration MEK ERK"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0,"dc:description":"cannot score as this assay does not differentiate NS from other RAS disorders"},{"id":"cggv:bb7c35d9-7bf5-4a28-96f3-9fe4047722b4","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:9bad798f-c94b-41a9-b263-d422fac30697","type":"FunctionalAlteration","dc:description":"The p.Ile326Val variant showed no significant difference from the WT. The p.Glu501Lys variant showed significantly impaired activity to the WT.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/17603482","type":"dc:BibliographicResource","dc:abstract":"Noonan syndrome is characterized by short stature, facial dysmorphia and a wide spectrum of congenital heart defects. Mutations of PTPN11, KRAS and SOS1 in the RAS-MAPK pathway cause approximately 60% of cases of Noonan syndrome. However, the gene(s) responsible for the remainder are unknown. We have identified five different mutations in RAF1 in ten individuals with Noonan syndrome; those with any of four mutations causing changes in the CR2 domain of RAF1 had hypertrophic cardiomyopathy (HCM), whereas affected individuals with mutations leading to changes in the CR3 domain did not. Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation, and zebrafish embryos with morpholino knockdown of raf1 demonstrated the need for raf1 for the development of normal myocardial structure and function. Thus, our findings implicate RAF1 gain-of-function mutations as a causative agent of a human developmental disorder, representing a new genetic mechanism for the activation of the MAPK pathway.","dc:creator":"Razzaque MA","dc:date":"2007","dc:title":"Germline gain-of-function mutations in RAF1 cause Noonan syndrome."},"rdfs:label":"HEK293 variants"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0,"dc:description":"cannot score as this assay does not differentiate NS from other RAS disorders"}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:27cdf120-3d36-4a36-8cc3-78ec7f3cb5c2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:48a97cad-6fbb-48ec-93e4-33046a2a5057","type":"Proband","detectionMethod":"This study screened 23 NS patients for variants in \"the genes known for NS\" using Sanger sequencing. They also took a detailed clinical examination of the ocular phenotypes of all the patients. They identified 1 individual with a variant in BRAF. This variant has been identified in 2 other indiviuals with CFCS (Gripp 2007, Schulz 2008).","phenotypeFreeText":"myopia; astigmatism; epicanthus; hypertelorism; unilateral ptosis; lower eyelid retraction; esotropia; abnormality of eye movement; prominent corneal nerve fibers; optic nerve hypoplasia","sex":"Male","variant":{"id":"cggv:27cdf120-3d36-4a36-8cc3-78ec7f3cb5c2_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8a6f4f38-20b1-404f-b63b-cf611c5487db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.730A>C (p.Thr244Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA280025"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27521173","type":"dc:BibliographicResource","dc:abstract":"To determine the full spectrum of ocular manifestations in patients with Noonan syndrome (NS).","dc:creator":"van Trier DC","dc:date":"2016","dc:title":"Ocular Manifestations of Noonan Syndrome: A Prospective Clinical and Genetic Study of 25 Patients."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27521173","rdfs:label":"Patient No. 19"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"Absent from gnomAD but indufficient evidence for impact  and variant has been identified in a CFC patient"},{"id":"cggv:a31f60aa-67c8-49f9-be5c-84f2512aba26_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d8c6d9ff-b44e-48f4-9c93-b152e6f77564","type":"Proband","phenotypeFreeText":"Genotype/phenotype correlation. No specific patient information given.","sex":"UnknownEthnicity","variant":{"id":"cggv:a31f60aa-67c8-49f9-be5c-84f2512aba26_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6ef83b11-dd38-4c22-9b35-7f2912fcce13","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.1510G>C (p.Gly504Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/279992"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21784453","type":"dc:BibliographicResource","dc:abstract":"To investigate mutation spectrums and their correlations to phenotypes in Noonan syndrome (NS) and NS-related disorders that share functional alterations of the Ras-mitogen-activated protein kinase pathway.","dc:creator":"Lee BH","dc:date":"2011","dc:title":"Spectrum of mutations in Noonan syndrome and their correlation with phenotypes."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21784453","rdfs:label":"Lee_1"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"Variant absent from gnomAD and predicted to be damaging. This study screened 59 Korean NS patients for variants in PTPN11, SOS1, KRAS, HRAS, NRAS, RAF1, BRAF, SHOC2, MEK1, and MEK2 using an ABI3130x1 Genetic Analyzer. They identified a BRAF variant in 1 NS patient. This variant was also reported in a CFC patient by Nava et al. 2007. No further info given, and variant reported in CFC so cannot score"},{"id":"cggv:2b279f61-c847-47c9-9119-f2c0823f704b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:1c10c24a-d9e2-4ba0-b1b1-be0d37b9ee60","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"detectionMethod":"Parental DNA not available.  This study screened 270 NS patients, 6 NSML patients, and 33 CFCS for variants in BRAF. All patients were negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, and MEK2. Patients were screened using DHPLC followed by dye terminator sequencing. Genotyping of parents was done in all available families in which a BRAF variant was found. This variant was absent from 150 ethnically matched controls.","phenotypeFreeText":"fetal macrosomia; feeding difficulties in infancy; short stature; dolichocephaly; prominent forehead; narrow forehead; downslanted palpebral fissures; hypertelorism; palpebral thickening; ptosis;  thick vermilion border; low-set ears; thickened helices; large earlobe; mandibular prognathia; low posterior hairline; curly hair; nevus; multiple lentigines; short neck; webbed neck; cubitus valgus; shield chest; joint hypermobility; scoliosis; intellectual disability; strabismus; delayed puberty","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, MEK2.","sex":"Female","variant":{"id":"cggv:2b279f61-c847-47c9-9119-f2c0823f704b_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:29ded25f-7ce3-4804-a94f-ee08d85bf159","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.722C>T (p.Thr241Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29805"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169","rdfs:label":"N02"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"absent from gnomAD without further evidence of impact."},{"id":"cggv:33828aaa-6488-48c5-bb6b-75af50b8716a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0361bb48-791e-42b9-8a2a-a3a88e23ef36","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"This study screened 31 children diagnosed with a RASopathy (8 CFC, 23 NS) for variants in BRAF, KRAS, MEK1, and MEK2. The children had previously been screened for variants in PTPN11. They identified a BRAF variant in one child with NS.","phenotypeFreeText":"short stature; global developmental delay; muscular hypotonia; feeding difficulties in infancy; proptosis; hypertelorism; sensorineural hearing impairment; low-set ears; deep philtrum; macrocephaly; triangular face; low posterior hairline; enlarged thorax; pectus excavatum; cubitus valgus; cryptorchidism; splenomegaly; inguinal hernia; curly hair; melanocytic nevus","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11.","sex":"Male","variant":{"id":"cggv:33828aaa-6488-48c5-bb6b-75af50b8716a_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:3273420c-8f5b-42f4-a2d0-890360b50139","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.1615A>G (p.Lys539Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13976"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/18456719","type":"dc:BibliographicResource","dc:abstract":"Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFC) are related disorders associated with disrupted RAS/RAF/MEK/ERK signalling. NS, characterised by facial dysmorphism, congenital heart defects and short stature, is caused by mutations in the genes PTPN11, SOS1, KRAS and RAF1. CFC is distinguished from NS by the presence of ectodermal abnormalities and more severe mental retardation in addition to the NS phenotype. The genetic aetiology of CFC was recently assigned to four genes: BRAF, KRAS, MEK1 and MEK2.","dc:creator":"NystrÃ¶m AM","dc:date":"2008","dc:title":"Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/18456719","rdfs:label":"Patient 8"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"absent from gnomAD but no further evidence of impact"}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":0},{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:5e4a6abc-b3fc-41f7-a009-b468cbeaf6cf_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1ef455b4-7d16-4161-8b6e-f7d938cbe688","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"phenotypeFreeText":"feeding difficulties in infancy; short stature; dolichocephaly; prominent forehead; narrow forehead; hypetelorism; depressed nasal bridge; low-set ears; thickened helices; nevus; multiple lentigines; cubitus valgus; shield chest; joint hypermobility; intellectual disability; generalized hypotonia; strabismus","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, MEK2.","sex":"Female","variant":{"id":"cggv:5e4a6abc-b3fc-41f7-a009-b468cbeaf6cf_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:e0d8eb05-1ad4-4985-bf94-88da08f697ce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.1713G>C (p.Trp571Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29808"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169","rdfs:label":"N04"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:99a83f8f-6a94-4c17-b742-8872368cea1d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:80479d06-ddcf-4410-9c80-87ca42ffd227","type":"Proband","detectionMethod":"This study screened 58 NS patients for variants in ARAF, BRAF, RAF1, MAP2K1, and MAP2K2 using dye terminator sequencing. They identified one individual with two variants in  the BRAF gene. The p.I326V variant was present in the mother although it was not made clear whether or not she was affected. The p.E501K variant occured de novo and was functionally shown to impair kinase activity.","phenotypeFreeText":"No specific patient phenotype given.","sex":"Female","variant":{"id":"cggv:99a83f8f-6a94-4c17-b742-8872368cea1d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:90d19b9c-ea0c-41f2-a551-cc439a9ee907","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.1621G>A (p.Glu541Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13977"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17603482"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/17603482","rdfs:label":"Razzqaue_1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2,"dc:description":"Variant was ID'd as de novo and was shown to functionally impair kinase activity. absent from gnomAD."},{"id":"cggv:4ded97ff-cd85-4eb8-946d-ded9dcbea92b_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e5f6d7d4-d285-4a6b-8285-d291bc9478f3","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"firstTestingMethod":"PCR","phenotypeFreeText":"feeding difficulties in infancy; short stature; macrocephaly; dolichocephaly; hypertelorism; depressed nasal bridge; hyperhidrosis; deep palmar crease; multiple lentigines; cubitus valgus; pectus excavatum; joint hypermobility; scoliosis; intellectual disability; hypotonia; strabismus","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, MEK2.","sex":"Female","variant":{"id":"cggv:4ded97ff-cd85-4eb8-946d-ded9dcbea92b_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:e0d8eb05-1ad4-4985-bf94-88da08f697ce"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169","rdfs:label":"N03"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:2712e5a1-c3e0-43d2-a1ba-392e3b5fd10c_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:cc0a6ae8-b945-4147-aa77-5bcf6e1a29a0","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"phenotypeFreeText":"feeding difficulties in infancy; short stature; macrocephaly; prominent forehead; downslanted palpebral fissures; hypertelorism; ptosis; low-set ears; thickened helices; large earlobe; mandibular prognathia; low posterior hairline; atrial septal defect; short neck; webbed neck; pectus excavatum; intellectual disability; seizures; generalized hypotonia; ureteral obstruction; Arnold-Chiari type I malformation; pes planus","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, MEK2.","sex":"Female","variant":{"id":"cggv:2712e5a1-c3e0-43d2-a1ba-392e3b5fd10c_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:03ac4cfd-eaf2-4cc5-a402-2776a3eb42c5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.1909C>G (p.Leu637Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/13969"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169","rdfs:label":"N05"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:8c87a2df-a29e-4d34-bc3f-181d2dcf91a0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:9348250d-fd1b-42ec-b70c-7bae853e8886","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":1,"phenotypeFreeText":"large for gestational age; feeding difficulties in infancy; short stature; macrocephaly; dolichocephaly; prominent forehead; narrow forehead; downslanted palpebral fissures; hypertelorism; palpebral thickening; ptosis; depressed nasal bridge; thick vermilion border; low-set ears; thickened helices; pulmonic stenosis; dysplastic pulmonary valve; shield chest; intellectual disability; seizures; generalized hypotonia","previousTesting":true,"previousTestingDescription":"Negative for variants in PTPN11, SOS, KRAS, HRAS, RAF1, MEK1, MEK2.","sex":"Female","variant":{"id":"cggv:8c87a2df-a29e-4d34-bc3f-181d2dcf91a0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:31b834aa-5a8e-4369-af8d-45128a232d44","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001374258.1(BRAF):c.722C>G (p.Thr241Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29806"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19206169","rdfs:label":"N06"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":10}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":10}],"evidenceStrength":"Moderate","sequence":2153,"specifiedBy":"GeneValidityCriteria5","strengthScore":10.5,"subject":{"id":"cggv:9fb7e3f6-81e0-45e4-b56f-ddde78190a95","type":"GeneValidityProposition","disease":"obo:MONDO_0018997","gene":"hgnc:1097","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","dc:description":"There was sufficient genetic evidence in the literature for the association between BRAF and Noonan syndrome (NS) to be classified as Moderate. However, variable expressivity, age of ascertainment, and outdated clinical assessments of affected individuals may complicate the clinical diagnosis of NS versus cardiofaciocutaneous syndrome (CFC). Additional genotype-phenotype correlations are necessary to solidify the association of BRAF with Noonan syndrome (Lee et al., 2011; Nystrom et al., 2008; Razzaque et al., 2007; Sarkozy et al., 2009; van Trier et al., 2016). The BRAF gene is also located in the Ras/MAPK pathway which is associated with the NS phenotype (Aoki, Niihori, Inoue, & Matsubara, 2016; Rauen, 2013). Of note, BRAF has also been classified as definitive in association with CFC, limited in association with NS with multiple lentigines, and disputed in association with Costello syndrome. The ClinGen RASopathy Expert Panel found no evidence associating BRAF with NS with loose anagen hair. This curation was approved by the ClinGen RASopathy Gene Curation Expert Panel on 7/24/18 (SOP Version 5).","dc:isVersionOf":{"id":"cggv:47cf08d5-efc6-4d42-b031-a06619873161"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}